Arnold Pharma announces the early preclinical data of Anti-hTNFR2 (AN3025) at the American Association for Cancer Research (AACR) 2021 Annual Meeting

Arnold Pharma, an innovative global biopharmaceutical company focusing on the field of tumor treatment, recently announced that it will announce the pre-clinical version of anti-hTNFR2 (AN3025) at the American Association for Cancer Research (AACR) 2021 annual meeting in the form of an electronic poster.
The data and summary content have been published on the AACR official website
.

The AACR annual meeting will be held in the form of virtual meetings on April 10-15 and May 17-21, Eastern Time

The published research results are as follows:

Abstract/Poster Number: 1452

Title: AN3025: Immunostimulatory anti-hTNFR2 antibody with good anti-tumor activity?

Sub-venue category: drug research and development for the tumor microenvironment

The AN3025 antibody firstly uses the rabbit's immune system to generate initializing antibodies, then screens and purifies them using phage display technology, and then humanizes them by CDR transplantation
.

In order to evaluate the pharmacological properties and anti-tumor activity of the antibody, Arnold Pharma has carried out a series of early preclinical research trials

The above test results show that the AN3025 antibody shows extremely high affinity in binding to human TNFR2 and can block the interaction between TNFR2 and TNF
.

The antibody showed a certain promotion effect on the production of interferon-γ (IFN-γ) in the Treg/Teff co-culture test, and significantly inhibited the growth of MC38 tumors in the hTNFR2 mouse model alone administration test

“In pre-clinical research, the AN3025 project has proven its great potential in tumor control,” said Dr.
He Nanhai, head of Arnold Pharmaceuticals’ drug development.
“We will continue to advance this exciting project and look forward to its development.
Enter the clinical stage in the near future
.

"

       About AN3025

       AN3025 is a new type of humanized IgG1 anti-hTNFR2 antibody, currently in the preclinical development stage
.

The antibody binds to the extracellular domain of human cells TNFR2 with sub-nanomolar affinity, and prevents its ligand TNF from binding to TNFR2

       About Arnold Pharma

       Arnold Pharma is a clinical-stage global biopharmaceutical company focusing on the development of innovative oncology drugs
.

It has R&D and clinical operation centers in both China and the United States .

       Arnold Pharma has established a competitive management team and built a unique drug development technology platform.
At the same time, it has established strategic partnerships with many top pharmaceutical companies in the world
.

Arnold Pharma is committed to becoming an innovative R&D company that creates "global new" oncology drugs, bringing more effective treatments to patients in China and even the world, and realizing the mission of turning cancer into a non-fatal disease and even curing